Agentic AI Powers U.S. Healthcare Stocks
Healthcare payrolls keep climbing, and hospital systems, payers, and clinics are now openly treating agentic AI as the cheapest unit of labor on the market.
EVH - Evolent Health, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$6.30
DETAILS
HIGH:
$10.00
LOW:
$3.50
MEDIAN:
$6.00
CONSENSUS:
$6.30
UPSIDE:
59.49%
Stock News
Evolent Health Q1 Earnings Call Highlights
Evolent Health NYSE: EVH reported first-quarter 2026 results that management said were in line with expectations, while reiterating its full-year outlook and highlighting new contract wins, early progress on major client launches and continued investment in automation.
Evolent Health, Inc. (EVH) Q1 2026 Earnings Call Transcript
Evolent Health, Inc. (EVH) Q1 2026 Earnings Call Transcript
Compared to Estimates, Evolent Health (EVH) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Evolent Health (EVH) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Evolent Health (EVH) Reports Q1 Loss, Misses Revenue Estimates
Evolent Health (EVH) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to earnings of $0.06 per share a year ago.
Evolent Announces First Quarter 2026 Results
WASHINGTON, May 7, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended March 31, 2026. Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "I am happy with the strong start to the year.
Evolent To Release First Quarter 2026 Financial Results on Thursday, May 7, 2026
WASHINGTON, April 7, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its first quarter 2026 financial results on Thursday, May 7, 2026, before market open, with a conference call to follow at 8 a.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference call found on Evolent's investor relations website, https://ir.evolent.com.
Evolent Health, Inc (NYSE:EVH) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Evolent Health, Inc (NYSE: EVH - Get Free Report) has earned an average rating of "Moderate Buy" from the seventeen analysts that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have given a hold rating and thirteen have given a buy rating to the company.
Evolent announces appointment of Archie Mayani as chief product officer
Industry veteran brings track record of innovation from GHX, Change Healthcare, UnitedHealth Group and Amazon. WASHINGTON, March 19, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced the appointment of health care technology leader and AI innovator Archie Mayani as chief product officer (CPO).
8 Knots Management LLC Lowers Position in Evolent Health, Inc $EVH
8 Knots Management LLC trimmed its holdings in shares of Evolent Health, Inc (NYSE: EVH) by 39.3% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,768,113 shares of the technology company's stock after selling 1,145,022 shares during the
Evolent to Participate in Upcoming Investor Conferences
WASHINGTON, Feb. 26, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced that members of its executive management team will participate in upcoming investor conferences. A live audio-only webcast and replay for these events will be available on the "Events and Presentations" section of Evolent's investor relations website.
Evolent Health: Cheap, Levered, But Ready To Rebound
Evolent Health, Inc. is rated a Buy, with turnaround momentum and risk/reward now favoring upside after recent operational and strategic shifts. EVH's Performance Suite model now covers ~90% of revenue, offering risk protection and greater earnings predictability, despite near-term profit headwinds from new contract launches. Oncology drives EVH's growth, with strong customer retention (>98%) and cost discipline via AI automation and workforce efficiencies delivering $20M+ in annualized savings.
Evolent Health, Inc. (EVH) Q4 2025 Earnings Call Transcript
Evolent Health, Inc. (EVH) Q4 2025 Earnings Call Transcript
Compared to Estimates, Evolent Health (EVH) Q4 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Evolent Health (EVH) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Evolent Health (EVH) Q4 Earnings Top Estimates
Evolent Health (EVH) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to a loss of $0.02 per share a year ago.
Evolent Announces Fourth Quarter 2025 Results and Full Year 2025 Results
WASHINGTON, Feb. 24, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended December 31, 2025. Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "In 2025 we executed on our earnings targets, continued to grow market share, renewed customers at strong rates, and continued the migration of Performance Suite clients to our enhanced Performance Suite contract model.
Evolent Health (NYSE:EVH) Share Price Crosses Below Fifty Day Moving Average – Should You Sell?
Shares of Evolent Health, Inc (NYSE: EVH - Get Free Report) crossed below its 50-day moving average during trading on Monday. The stock has a 50-day moving average of $3.69 and traded as low as $2.62. Evolent Health shares last traded at $2.7850, with a volume of 2,872,468 shares traded. Analyst Ratings Changes A number
Evolent To Release 2025 Fourth Quarter and Year-End Financial Results on Tuesday, February 24, 2026
WASHINGTON, Feb. 4, 2026 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its 2025 fourth quarter and year-end financial results on Tuesday, February 24, 2026, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference call found on Evolent's investor relations website, https://ir.evolent.com.
Price Targets
Evolent Health price target raised to $6 from $5 at Canaccord
$6.00
(was $3.96)
Canaccord Genuity
Evolent Health price target lowered to $6 from $10 at Truist
$6.00
(was $3.05)
Truist Financial
Evolent Health (EVH) PT Lowered to $3.50 at BMO Capital
$3.50
(was $3.03)
Sean Dodge
·
BMO Capital
Evolent Health price target lowered to $10 from $16 at BTIG
$10.00
(was $3.21)
David Larsen
·
BTIG
Evolent Health (EVH) PT Lowered to $6 at Piper SandlerMember Login
$6.00
(was $3.83)
Piper Sandler
Evolent Health price target lowered to $14 from $27 at UBS
$14.00
(was $9.97)
Kevin Caliendo
·
UBS
Evolent dips after Truist warns guidance may be 'significantly' below consensus
$20.00
(was $9.97)
Jailendra Singh
·
Truist Financial
Evolent Health (EVH) PT Lowered to $17 at RBC Capital as Membership Declines
$17.00
(was $11.96)
Sean Dodge
·
RBC Capital
Evolent Health price target lowered to $18 from $27 at JMP Securities
$18.00
(was $12.54)
Constantine Davides
·
JMP Securities
Evolent Health (EVH) PT Lowered to $28 at Oppenheimer
$28.00
(was $12.59)
Mohan Naidu
·
Oppenheimer
Evolent weakness linked to elevated Medicaid MLRs at peers, says Stephens
$38.00
(was $24.95)
Jeff Garro
·
Stephens
Evolent Health upgraded to Buy from Hold at Truist
$33.00
(was $20.87)
Jailendra Singh
·
Truist Financial
RBC Capital Reiterates Outperform Rating on Evolent Health (EVH)
$42.00
(was $22.04)
Sean Dodge
·
RBC Capital
Evolent Health (EVH) PT Lowered to $28 at Truist Securities
$28.00
(was $23.75)
Jailendra Singh
·
Truist Financial
Piper Sandler Reiterates Overweight Rating on Evolent Health (EVH)
$51.00
(was $29.60)
Jessica Tassan
·
Piper Sandler
Evolent Health (EVH) PT Lowered to $44 at Canaccord Genuity
$44.00
(was $32.73)
Richard Close
·
Canaccord Genuity
BTIG Maintains Buy on Evolent Health, Raises Price Target to $50
$50.00
(was $35.21)
BTIG
Canaccord Genuity Maintains Buy on Evolent Health, Raises Price Target to $45
$45.00
(was $26.91)
Canaccord Genuity